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We designed a method to generate antibiotic-resistant strains of Streptococcus 
pneumoniae at frequencies 4 orders of magnitude greater than the spontaneous 
mutation rate. The method is based on the natural ability of this organism to be 
genetically transformed with PCR products carrying sequences homologous to its 
chromosome. The genes encoding the targets of ciprofloxacin (parC, encoding the ParC 
subunit of DNA topoisomerase IV), rifampin (rpoB, encoding the  subunit of RNA 
polymerase) and streptomycin (rpsL, encoding the S12 ribosomal protein) from the 
susceptible laboratory strain R6 were amplified by PCR and used to transform the same 
strain. Resistant mutants were obtained with a frequency of 10-4 to 10-5, depending on 
the fidelity of the DNA polymerase employed in PCR amplifications. Ciprofloxacin-
resistant mutants, with MICs 4-to-8-fold higher than that of R6, carried single 
mutations at residues of the quinolone-resistance determining-region: S79 (change to A, 
F or Y) or D83 (change to N or V). Rifampin-resistant strains, with MICs at least 133-
fold higher than that of R6, contained single mutations within the cluster I of rpoB: S482 
(change to P), Q486 (change to L), D489 (change to V) or H499 (change to L or Y). 
Streptomycin-resistant mutants, with MICs at least 64-fold higher than that of R6, 
carried mutations at either K56 (change to I, R or T) or K101 (change to E). PCR 
products obtained from the mutants were able to transform R6 to resistance with high 
efficiency (>104). This method could be used to efficiently obtain resistant mutants for 





Streptococcus pneumoniae, the pneumococcus, is the human pathogen responsible for 
most community-acquired pneumonia, meningitis and otitis media, causing about three 
million deaths annually in children in the developing world (15). Since the 1990’s, the 
number of pneumococcal clinical isolates resistant to the major therapeutic drugs, including 
new ones such as the fluoroquinolones (5, 27) has been increasing worldwide (9, 18, 33) and 
is becoming a major problem for public health. In this scenario, studies on the mechanisms 
involved in antibiotic resistance are of primary importance. These studies rely mainly on the 
identification of the antibiotic targets by locating the mutations involved in resistance and on 
biochemical studies of inhibition mechanisms. A significant progress in this direction has 
been the determination of the complete genome sequences of the laboratory R6 pneumococcal 
strain (19), of a serotype 4 isolate (40), and most of a serotype 19F isolate (7). Deciphering 
the role of these genomic sequences implies the generation of large theoretical information 
that must be corroborated experimentally by molecular biology. However molecular methods 
for S. pneumoniae are still limited (22) despite its high clinical importance. On the other hand, 
it is well known that S. pneumoniae is a natural-competent bacterium and methods for its 
transformation under laboratory conditions have been developed. Competence state is a 
process dependent on cell density triggered by the accumulation in the medium of the 
competence-stimulating peptide that signals the two-component ComD - ComE system (16, 
35), which results in the transcriptional activation of a competence-specific sigma factor (26). 
This factor enables transcription of the late competence genes that encode enzymes for the 
binding, uptake, and recombination of the donor DNA with the chromosome (3, 24, 36).  
We have recently obtained several mefloquine-resistant pneumococcal mutants by 
using PCR amplification of fragments of the genes atpC and atpA encoding the c and a 
subunits of the F0F1 ATPase, respectively (10, 29). Transformation with these PCR products 
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obtained from strain R6 and selection of transformants in inhibitory mefloquine 
concentrations rendered mutants at a frequency several orders of magnitude greater than the 
spontaneous mutation rate. The information provided by the new mutants has significantly 
contributed   to our understanding of the arrangement of the F0F1 ATPase (28). It was 
proposed that those mutants were originated as a result of the error rate of the DNA 
polymerase used in the PCR amplifications (28). In this work, we present evidence supporting 
this hypothesis and that the method is useful for obtaining S. pneumoniae mutants at high 
frequency in, at least, three genes, parC, rpoB, and rpsL known to be targets of ciprofloxacin 
(CIP) (20, 30, 34, 39), rifampin (RIF) (8, 32) and streptomycin (STR) (37), respectively.  
While this manuscript was in preparation, a PCR-based approach to drug target 
identification in S. pneumoniae was published (2). Although PCR methodology and the 
natural transformability of the pneumococcus are the bases of both studies, our work has been 
focused on the generation and characterization of the antibiotic-resistant pneumococcal 
transformants. 
 
MATERIALS AND METHODS 
 
 Bacterial strains, growth and transformation of bacteria. S. pneumoniae strains used 
were the laboratory strain R6, ATCC 49619 strain, the STR-resistant (StrR) strain 533 (str-41, 
sul, nov-1, ery) and the CIP-resistant (CipR) clinical isolate 4114. S. pneumoniae was grown in a 
casein hydrolysate-based medium with 0.2% sucrose (AGCH) as energy source and transformed 
as described (23). Strain R6 was used as recipient in transformation experiments. Cultures 
containing 9 × 106 CFU per ml were treated with DNA at 0.15 g/ml for 40 min at 30ºC, then at 
37ºC for 90 min, before plating on media plates containing 2 µg/ml of CIP, 1 µg/ml of RIF, or 
100 µg/ml of STR. Colonies were counted after 24 h growth at 37 ºC in a 5% CO2 atmosphere 
in AGCH medium with 1% agar. Rates of spontaneous mutation to drug resistance were 
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estimated by plating 2 × 1010 cells in 1 g/ml RIF or 100 g/ml STR. 
DNA techniques. S. pneumoniae chromosomal DNA was prepared as previously 
described (14). Synthetic oligonucleotide primers used in PCR amplifications and in 
sequencing reactions are listed in Table 1 and were designed based on the previously 
published sequences of the corresponding genes of strain R6 (11, 19, 30). Amplifications 
were performed with 1 U of Thermus thermophilus (Tth) thermostable DNA polymerase 
(Biotools) or 2,5 units of a proof-reading enzyme, Expand High Fidelity PCR (Hf) system 
(Boehringer Manheim), 1 µg of genomic DNA, 0.4 M (each) of the corresponding synthetic 
oligonucleotide primers, 0.2 mM of each dNTP, and 2 mM MgCl2 in a final volume of 50 l. 
Amplification was carry out with an initial cycle of 1 min denaturation at 94ºC, 30 cycles of 
30 s at 94ºC, 90 s at 55ºC and a 75 s polymerase extension step at 72ºC, and a final 8-min step 
followed by slow cooling to 4ºC. The remaining dNTPs and primers were removed from PCR 
products using HR S-400 columns (Amersham) prior to sequencing or transformation. 
Sequencing was done on both DNA strands according to manufacturers protocols using an 
Applied Biosystems Prism 377 DNA sequencer 
Minimal inhibitory concentration (MIC) determination. MICs were determined by 
the microdilution method, using cation-adjusted Mueller-Hinton broth (Difco) supplemented 
with 2.5% lysed horse blood as recommended by the National Committee for Clinical 
Laboratory Standards (31). Mueller-Hinton agar plates (Difco) supplemented with 5% 
defibrinated sheep blood were used to grow the strains overnight. The inoculum was prepared 
by suspension of several colonies in Mueller-Hinton broth and adjusting the turbidity to the 
0.5 McFarland standard (ca. 108 CFU/ml). The suspension was further diluted to provide a 
final bacterial concentration of 104 CFU/ml in each well of the microdilution trays. Plates 
were covered with plastic tapes and incubated in ambient atmosphere at 37ºC for 20-24 h. 
MIC was defined as the lowest concentration of drug that inhibited visible growth. The S. 
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pneumoniae strains ATCC 49619 and R6 were used for quality control. CIP was kindly 




Construction of resistant strains by PCR and transformation. Fragments of about 
1,600 bp were amplified by PCR from S. pneumoniae R6 by using specific oligonucleotides: 
parCUP and parC503R for parC; rpoB227 and rpoB773R for rpoB; rpsLUP and rpsLDOWN 
for rpsL (Table 1, Fig.1). The 1,629-bp parC PCR fragment has the sequence encoding the 
first 508 amino acid (aa) residues of the 824-residue-ParC subunit of the DNA topoisomerase 
IV, and includes the quinolone-resistance determining region (QRDR, 30). The 1,641-bp 
rpoB PCR fragment codes for 547 residues (residues 227 to 554) of the central region of the  
subunit of the RNA polymerase. The 1,615-bp rpsL PCR fragment includes the coding region 
for the first 320 residues of Spr0247, a putative alkaline amylopullulanase, the rpsL gene that 
encodes the 137-residues-long 30S ribosomal protein S12, and most (149 residues out of 156) 
of the 30S ribosomal protein S7 encoded by the rpsG gene. These R6-PCR derived fragments 
were used to transform competent R6 cells and transformants were selected on CIP at 2 g/ml 
(4-fold the MIC of R6), RIF at 1 g/ml (higher than 33-fold the MIC of R6), or STR at 100 
g/ml (32-fold the MIC of R6). These antibiotic concentrations were chosen taking into 
account the levels of resistance to these drugs achieved by single mutations in parC (30), 
rpoB (8, 32) and rpsL (37). The frequency of resistant mutants obtained by transformation 
was of 1−12.4  10-5 and 0.4−6.4  10-5 when using PCR products amplified with Tth or Hf, 
respectively (Table 2). In consequence, 2−4 fold more transformants appeared with the Tth 
enzyme, consistent with the error-rate differences (3-fold) of these polymerases reported by 
the manufacturers. Transformants resistant to a particular antimicrobial agent appeared only 
when the corresponding target gene was present in the PCR product used as donor DNA, 
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whereas no colonies were detected when other antimicrobial agents were used for selection 
(Table 2). In this way, transformants resistant to either CIP, RIF, or STR appeared when the 
PCR products contained parC, rpoB, or rpsL, respectively. The MICs for the mutant strains 
showed increments in resistance of 4−8 fold for CIP, at least 133-fold for RIF, and at least 64-
fold for STR (Table 3).  
Characterization of antibiotic-resistant strains. Ten resistant mutants for each 
antibiotic were chosen and pertinent regions (Fig. 1) of the parC, rpoB and rpsL genes were 
sequenced. A region of 310-bp encoding ParC residues 50 to 172 was amplified and 
sequenced with oligonucleotides parC50 and parC152 (Table 1). The 10 CipR strains carried 
single mutations affecting residues S79 or D83 of the ParC QRDR (Table 3). A 380-bp region 
of rpoB coding for residues 427-to-554 was amplified and sequenced with oligonucleotides 
rpoB427 and rpoB554R. The RIF-resistant (RifR) strains carried mutations affecting residues 
S482, Q486, D489 or H499. A 378-bp fragment of rpsL encoding residues 6-to-131 of the 
S12 ribosomal protein from the StrR strains was also amplified and sequenced with 
oligonucleotides rpsL6 and rpsL131R, showing mutations that would produce changes at K56 
or K101.  
Genetic evidence demonstrating that the mutations carried by the resistant strains were 
indeed involved in resistance was obtained by genetic transformation. PCR products of about 
1,600 bp amplified from the CipR, RifR, and StrR strains described above were able to 
transform strain R6 with high efficiency (0.2to14  105 transformants/ ml) to resistance 
(Table 3). Two independent colonies from each of these transformation experiments were 
selected and analyzed. Their MICs and mutations were identical to that of the parental CipR, 
RifR or StrR strain (not shown). These results confirmed the relationship between aa change 





 In the present study we describe a simple method to obtain antibiotic-resistant strains of 
S. pneumoniae taking advantage of the PCR methodology, the error rate of the DNA 
polymerases used in the amplifications and of the natural transformation ability of S. 
pneumoniae. The appearance of resistant colonies upon transformation with the 1,600 bp PCR 
products carrying the appropriate R6 genes could be attributed to the error rate of the 
polymerase. This rate is of 1 error/10 kb, therefore 1.6 errors would be expected for 10 
molecules of 1,600 bp. Since 4.5 × 105 competent cells (5% of 9 × 106 CFU) could be 
transformed with chromosomal DNA in our   experiments, the total number of putative 
mutants would be of about 7.2 × 104. From our results, of the putative nucleotide changes that 
would occur in the parC-PCR fragment (encoding 508 residues of ParC) and at the rpsL-PCR 
fragment (encoding 320 residues of Spr0247, 137 of RpsL, and 149 of RpsG), only changes at 
2 residue positions conferred CIP-resistance (0.4%) or STR-resistance (0.3%). However, of 
the putative nucleotide changes that would occur in the rpoB PCR fragment (encoding 547 
residues of the  subunit of RNA polymerase) changes at 4 residue positions conferred RIF-
resistance (0.7%) (Table 3). If we introduce these corrections, among 7.2 × 104 putative 
mutants, the expected number of resistant clones would be approximately 3 × 102 for CipR, 2 
× 102 for StrR and 5 × 102 for RifR. These figures are consistent with the number of drug-
resistant clones    (0.9 × 102 of CipR, 3 × 102 of StrR and 1 × 103 of RifR) obtained, and are also 
in line with those previously reported for RIF and STR (2) and with the frequencies reported 
for mefloquine-resistant mutants (28).  
 The method allowed obtaining mutants with frequencies several orders of magnitude 
higher than that of spontaneous mutation. The frequency of mutation to CipR, RifR and StrR in 
S. pneumoniae has been shown to be in the range 10−8−10−9 (2, 34, our own results) whereas 
the transformation frequencies to CipR, RifR and StrR with the corresponding PCR products 
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were about 10−5, 10−4, and 10−5, respectively (Table 3).  
 Among the 10 resistant mutants for each antibiotic sequenced, five CipR, five RifR and 
four StrR different mutations were obtained. All ParC QRDR mutations found in the CipR 
strains obtained in this work had been previously described in laboratory or clinical isolates 
(1, 6, 20, 30, 34, 39). Although S79F and S79Y have been shown to be involved in resistance 
by transformation (20, 30, 39), the results presented in this work represent the first evidence 
that the S79A, D83N and D83V changes are involved in low-level CIP-resistance.  
All pneumococcal RifR strains obtained in this work had mutations at cluster I of rpoB 
(R6 residue positions 478 to 510), a conserved region where most of bacterial RifR mutations 
map (4, and references cited therein) and also where RifR mutations have been characterized 
in S. pneumoniae clinical isolates (8, 32). The RifR mutations found in this work were at 
residues S482, Q486, D489 and H499 (Table 3, Fig. 1). Structural and biochemical studies of 
Thermus aquaticus core RNA polymerase have revealed that RIF binds to a pocket of the 
RNA polymerase  subunit deep within the DNA/RNA channel and blocks the path of the 
elongating RNA when the transcript becomes 2 to 3 nt in length. Ten residues of cluster I are 
directly implicated in the interaction with RIF (4, 41). These residues are identical between 
Escherichia coli, Mycobacterium tuberculosis, and S. pneumoniae (6 of them are shadowed in 
Fig. 1). Three of them are the residues equivalent to those found mutated in RifR S. 
pneumoniae that established hydrogen bonds with the antibiotic: Q486, D489 and H499. 
These results suggest that the binding of RIF to S. pneumoniae RNA polymerase is similar in 
all bacterial enzymes. Accordingly, mutations altering D489 and H499 have been found in 
RifR S. pneumoniae clinical isolates (8, 32) and those altering the Q residue equivalent to S. 
pneumoniae R6 Q486 have been shown to be involved in RifR in E. coli (21, 38) and M. 
tuberculosis (17). However, no mutations at the residue equivalent to S482 of S. pneumoniae 
have been previously reported in other RifR bacteria (4, and references cited therein). This 
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residue does not make a direct interaction with RIF, although is conserved among bacterial  
subunits and in close proximity to the RIF binding pocket (4). The change of S482 by proline   
conferred low-level RIF resistance (CMI = 4 g/ml) to the RMJ4 strain (Table 3) and might 
affect the folding or packing of the protein in the local vicinity of this residue, causing 
distortions of the RIF binding pocket, as has been proposed for other RifR mutations that also 
map at residues surrounding this pocket (4).  
With respect to the StrR strains, mutations were found at two lysine residues, K56 and 
K101 (equivalent to K42 and K87 of E. coli). These two residues have been show to be 
involved in Str resistance in E. coli (13) and M. tuberculosis (12, and references cited 
therein), and the K56T change has been shown to be responsible for the StrR phenotype of S. 
pneumoniae 533 (37).  
 In summary, with the method described in this work, it was possible to construct CipR, 
RifR and StrR strains carrying mutations at specific gene regions. The same method might be 
used to construct all possible resistant mutants to other drugs. It would be also possible to 
make double mutants by sequential PCR and transformation cycles. Strains resistant to two (o 
more) antibiotics of the same family can be obtained in this way. The activity of the various 
antibiotics could be tested in the mutants obtained. This information would be useful to select 
the more adequate therapy, ideally, antibiotics not showing cross-resistance.  
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FIG. 1. Location of the PCR products employed in this work, of regions sequenced, and of the 
mutations present in the CipR (A), RifR (B) and StrR (C) strains. Black arrows (not draw to 
scale) indicate the oligonucleotides used to amplify the fragments of about 1,600 bp used in 
PCR experiments. Hatched rectangles correspond to the regions that have been sequenced to 
identify the mutations. AA substitutions present in the resistant strains are shown below the 
wild-type residue position (in boldface and underlined).  
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TABLE 1. Oligonucleotides used in this work 
 
Name Relevant features 
 Sequence (5'-3') Nt positions 
(aa positions)a 
parCUP GAACACGCCCTAGATACTGTG 103 to 83 of parC  
parC50 AAGGATAGCAATACTTT  147−163 of parC  
(50KDSNTF55) 
parC152 GTTGGTTCTTTCTCCGTATCG Complementary to 456−438 of parC 
(147DTEKEP152) 
parC503R GCCTTGGTCACGCTGACGTAGG Complementary to 1526−1505 of parC 
(502TYVSVTKA509) 
rpoB227 GCGAATTGGTTCGCAACACTG 680−700 of rpoB 
 (227ELVRNT233) 
rpoB427 CGGTTGGTGAATTGCTTGCCAACC 1282−1306 of rpoB 
 (427AVGELLAN435) 
rpoB554R  CAAGTGTCCGTAAGATGCAAG Complementary to 1641−1662 of rpoB 
(548LSSYGHL554) 
rpoB773R  GTCATGTAGGCAACGATTGGG Complementary to 2322−2301 of rpoB 
(768PIVAYMT774) 
rpsLUP GGGCTAGTAGAAGTAGTTGGC  320−300 of spr0247  
(101PTTSTSP107) 
rpsL6 CCAATTGGTTCGCAAACCGCG  15−35 of rpsL 
 (6QLVRKPR12) 
rpsL131R  CCGTATTTAGAACGGCCTTG Complementary to 392−373 of rpsL 
(125QGRSKYG131) 
rpsLDOWN  CGGAAGTGTGCGAATGCACGG Complementary to 443−426 of rpsG 
(143RMAEANR149) 
 
a Nt and AA numbering refers to the genes/proteins obtained from the S. pneumoniae R6 
sequence, taken the first Nt or AA as position 1.  
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TABLE 2. Antibiotic-resistant R6 transformants obtained with R6-PCR products  
 
  Transformants/ml (Transformation frequency × 10-5) selected on a 
Donor DNA Enzymeb CIP RIF STR 
parC Tth 94  21 (1.0) None None 
 Hf 33  22 (0.4) None None 
rpoB Tth None 1,119  319 (12.4) None 
 Hf None 580  193 (6.4) None 
rpsL Tth None None 299  88 (3.2) 
 Hf None None 72  28 (0.8) 
 
 
a 0.15 g of PCR products carrying the genes indicated were used to transform 1 ml (9  106 
CFU) of a competent R6 culture. Values (mean  standard deviation) of three independent 
experiments are represented. Transformation frequency: number of transformants/total 
number of cells. None, no transformants were observed when 300 l of the transformation 
mix were plated on selective plates, which gave a frequency < 4  10−7. PCR products used as 
controls were: a parC PCR product from a S. pneumoniae 4114 carrying a S79F change that 
yielded 2.0  1.5  104 transformants/ml, and a rpsL PCR product from S. pneumoniae 533 
(25) that carry a K56R (37) change that yielded 5.8  2.8  105 transformants/ml.  
b Tth: Thermus thermophilus thermostable DNA polymerase (Biotools); Hf: Expand High 
Fidelity PCR system (Boehringer Manheim).  
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CIP CMJ1 (4) parC S79F (TCTTTT) 4 (8) 4 
 CMJ2 (1)  D83N (GATAAT) 2 (4) 6 
 CMJ3 (1)  S79A (TCTGCT) 2 (4) 10 
 CMJ4 (2)  S79Y (TCTTAT) 4 (8 ) 27 
 CMJ10 (1)  D83V (GATGTT) 2 (4) 2 
RIF RMJ1 (5) rpoB Q486L (CAGCTG) 16 (> 533) 140 
 RMJ3 (1)  H499Y (CACTAC) 8 (> 266) 13 
 RMJ4 (1)  H499L (CACCTC) 16 (> 533) 43 
 RMJ5 (2)  S482P (TCACCA) 4 (>133) 14 
 RMJ7 (1)  D489V (GACGTC) 16 (> 533) 48 
STR SMJ1 (2) rpsL K56I (AAAATA) >800 (>256) 16 
 SMJ2 (6)  K56R (AAAAGA) >800 (>256) 7 
 SMJ4 (1)  K56T (AAAACA) >800 (>256) 27 
 SMJ6 (1)  K101E (AAAGAA) 200 (64) 43 
 
a AA positions of the genes indicated are according to the S. pneumoniae R6 genomic 
sequence. 
b MICs are the average of four independent determinations. Values in parentheses are the MIC 
value for the resistant strain divided by the MIC value for R6 (0.5 g/ml CIP, <0.03 g/ml 
RIF, and 3.12 g/ml STR).  
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c PCR products carrying parts of the indicated genes from resistant strains were used to 
transform R6 competent cells. PCR products used as controls were those indicated in Table 2.  
 
